Compugen (CGEN) news
Recent news
Compugen 2Q loss/share 7.0c, est. loss/share 8.0c
Compugen (CGEN) reported a second-quarter 2026 loss of $0.07 per share, matching the estimated loss of $0.08 per share. The results, announced on May 18, 2026, indicate that the company met expectations, with no deviation between actual and projected earnings per share. While the company has not…
AInvest Wire · Aug 3, 2026Compugen 2Q revenue $2.60M, estimate $2.27M
AInvest Wire · Aug 3, 2026Compugen to release second quarter 2026 results on Monday, August 3, 2026
AInvest Wire · Jul 20, 2026Compugen 1Q loss/share 8.0c, est. loss/share 7.1c
Compugen Ltd. (NASDAQ:CGEN) reported a first-quarter 2026 loss per share of 8.0 cents, slightly exceeding the estimated loss of 7.1 cents. The company’s Q1 2026 earnings reflect ongoing challenges in its immuno-oncology pipeline, particularly due to delays in licensing for its key asset, CGEN-301.…
AInvest Wire · May 18, 2026ImportantCompugen rockets 198% at open on anti-tumor drug deal with Gilead
Compugen rockets 198% at open on anti-tumor drug deal with Gilead Compugen, a clinical-stage cancer immunotherapy company, has recently announced a patent granted by the Japanese Patent Office for treating cancer with a triple combination of any anti-PVRIG antibody with any anti-TIGIT and anti-PD-1…
AInvest Wire · Dec 19, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.